The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.
 
Fei Ma
Research Funding - Shanghai Escugen Biotechnology
 
Fuming Qiu
No Relationships to Disclose
 
Zhongsheng Tong
Research Funding - Shanghai Escugen Biotechnology
 
Jiani Wang
No Relationships to Disclose
 
Yinuo Tan
No Relationships to Disclose
 
Rui Bai
No Relationships to Disclose
 
Qing Zhou
Employment - Shanghai Escugen Biotechnology
Leadership - Shanghai Escugen Biotechnology
Stock and Other Ownership Interests - Shanghai Escugen Biotechnology
Honoraria - Shanghai Escugen Biotechnology
Research Funding - Shanghai Escugen Biotechnology
Patents, Royalties, Other Intellectual Property - Shanghai Escugen Biotechnology
Travel, Accommodations, Expenses - Shanghai Escugen Biotechnology
Other Relationship - Shanghai Escugen Biotechnology
 
Xiaoyan Xing
Employment - Shanghai Escugen Biotechnology
Leadership - Shanghai Escugen Biotechnology
Honoraria - Shanghai Escugen Biotechnology
Research Funding - Shanghai Escugen Biotechnology
Travel, Accommodations, Expenses - Shanghai Escugen Biotechnology
Other Relationship - Shanghai Escugen Biotechnology